Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Vestcor Inc

Key Points

• Vestcor Inc increased its ownership in Charles River Laboratories International, Inc. by 208.6%, acquiring an additional 2,451 shares to reach a total of 3,626 shares valued at approximately $546,000.
• Institutional investors collectively own 98.91% of Charles River's stock, indicating significant confidence in the company's future.
• Analyst ratings for Charles River Laboratories vary, with one "sell," eleven "hold," and five "buy" ratings, and a consensus target price of $174.54.

Vestcor Inc grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 208.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,626 shares of the medical research company's stock after buying an additional 2,451 shares during the quarter. Vestcor Inc's holdings in Charles River Laboratories International were worth $546,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CRL. Rothschild Investment LLC grew its stake in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after buying an additional 144 shares in the last quarter. HM Payson & Co. acquired a new position in shares of Charles River Laboratories International in the first quarter worth about $31,000. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at approximately $37,000. GeoWealth Management LLC boosted its position in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the period. Finally, Huntington National Bank increased its position in shares of Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock worth $55,000 after acquiring an additional 164 shares during the period. Institutional investors own 98.91% of the company's stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president owned 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Price Performance

NYSE CRL traded down $0.54 on Thursday, reaching $149.79. 793,987 shares of the company's stock traded hands, compared to its average volume of 1,287,963. The stock has a market cap of $7.36 billion, a PE ratio of -230.88, a P/E/G ratio of 5.67 and a beta of 1.48. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $230.02. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The stock has a 50-day simple moving average of $155.03 and a 200 day simple moving average of $149.60.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The company had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $983.76 million. During the same quarter in the prior year, the business earned $2.80 earnings per share. Charles River Laboratories International's revenue for the quarter was up .6% compared to the same quarter last year. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Barclays boosted their price target on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and raised their target price for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research report on Wednesday, May 14th. Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen downgraded shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday, July 5th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $175.31.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).